http://biohealthinvestor.com Biotech and Medical Business Information Thu, 23 Feb 2012 17:49:36 +0000 http://backend.userland.com/rss092 en http://biohealthinvestor.com/2012/02/shouldnt-vivus-raise-capital-now-vvus.html http://biohealthinvestor.com/2011/12/can-human-genome-really-double-its-stock-price-hgsi.html http://biohealthinvestor.com/2011/11/alimera-implosion-analysis-what-is-next-alim-psdv.html http://biohealthinvestor.com/2011/11/implosion-analysis-for-targacept-what-lies-ahead-trgt-azn.html http://biohealthinvestor.com/2011/11/rare-analyst-calls-with-huge-upside-in-vical-and-vivus-vicl-vvus-bmy.html http://biohealthinvestor.com/2011/10/top-biotechs-with-upside-ahead-of-earnings-gild-amln-aria-incy-jazz-dndn-hgsi-ilmn-amgn-celg-biib-bmrn-life-regn-amln-cbst-onxx-thrx-vphm.html http://biohealthinvestor.com/2011/10/odds-making-on-a-human-genome-sciences-acquisition-hgsi-gsk-biib-mrk.html http://biohealthinvestor.com/2011/10/unusual-analyst-upgrade-endorsement-for-cell-therapeutics-ctic.html http://biohealthinvestor.com/2011/10/private-equity-changes-cro-landscape-with-ppd-buyout-ppdi-crl-cvd-prxl.html http://biohealthinvestor.com/2011/09/more-signs-of-life-for-obesity-drugs-vvus-orex-arna.html